Spots Global Cancer Trial Database for oncolytic virus
Every month we try and update this database with for oncolytic virus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | NCT05205408 | Advanced Solid ... | Oncolytic Virus... | 18 Years - | First Affiliated Hospital Bengbu Medical College | |
| OH2 Oncolytic Viral Therapy in Pancreatic Cancer | NCT04637698 | Pancreatic Canc... | OH2 injection | 18 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma | NCT03153085 | Melanoma Stage ... Melanoma Stage ... | TBI-1401(HF10) Ipilimumab | 20 Years - | Takara Bio Inc. | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | NCT05860374 | Sarcoma Carcinoma Breast Cancer Pancreatic Canc... Colorectal Canc... Gastric Cancer Liver Cancer Lung Cancer Gynecologic Can... | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer | NCT03916510 | Locally Advance... | Enadenotucirev Capecitabine Radiotherapy | 18 Years - | University of Oxford | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | NCT00625456 | Melanoma Lung Cancer Renal Cell Carc... Squamous Cell C... | Recombinant Vac... | 18 Years - | SillaJen, Inc. | |
| Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | NCT02062827 | Recurrent Gliob... Progressive Gli... Anaplastic Astr... | M032 (NSC 73397... | 18 Years - | University of Alabama at Birmingham | |
| A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer | NCT05830240 | Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc... | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | NCT02879760 | Non-Small Cell ... | Ad-MAGEA3 MG1-MAGEA3 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | NCT01443260 | Peritoneal Carc... | GL-ONC1 | 18 Years - | Genelux Corporation | |
| Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. | NCT01301430 | Glioblastoma Mu... | H-1PV | 18 Years - | Oryx GmbH & Co. KG | |
| GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | NCT06265025 | Head and Neck C... Malignant Melan... Colorectal Canc... Renal Cell Carc... Cervical Cancer Breast Cancer | GM103 (Part A) GM103 (Part B) GM103 and Pembr... | 18 Years - | GeneMedicine Co., Ltd. | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | NCT00554372 | Carcinoma, Hepa... | JX-594: Recombi... | 18 Years - | SillaJen, Inc. | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | NCT06171282 | Osteosarcoma Sarcoma Soft Tissue Sar... Bone Tumor | Recombinant onc... | 16 Years - 75 Years | Shanghai Yunying Medical Technology | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | NCT04050436 | Cutaneous Squam... Advanced Cutane... Metastatic Cuta... | Cemiplimab RP1 | 18 Years - | Replimune Inc. | |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | NCT01394939 | Colorectal Carc... CRC | JX-594 Irinotecan | 18 Years - | SillaJen, Inc. | |
| OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | NCT05248789 | Advanced Bladde... | OH2 injection | 18 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | NCT03954067 | Metastatic Canc... Solid Tumors Advanced Cancer | ASP9801 Pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy | NCT04695327 | Solid Tumor | TILT-123 | 18 Years - | TILT Biotherapeutics Ltd. | |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | NCT00554372 | Carcinoma, Hepa... | JX-594: Recombi... | 18 Years - | SillaJen, Inc. | |
| First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | NCT05648006 | Advanced Colore... | OH2 Capecitabine Bevacizumab | 17 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors | NCT06046742 | Solid Tumor | M1-c6v1 | 18 Years - | Guangzhou Virotech Pharmaceutical Co., Ltd. | |
| A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer | NCT06283121 | Gastric Cancer,... | BioTTT001 intra... SOX regimen toripalimab | 18 Years - | China Medical University, China | |
| Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 | NCT05222932 | Melanoma Head and Neck S... | TILT-123 Avelumab | 18 Years - | TILT Biotherapeutics Ltd. | |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | NCT02143804 | Bladder Cancer High Grade Non Muscle Inva... | oncolytic adeno... | 18 Years - | CG Oncology, Inc. | |
| Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder | NCT02723838 | Muscle-invasive... | REOLYSIN® Gemcitabine Cisplatin | 18 Years - | Oncolytics Biotech | |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | NCT02045602 | Locally Advance... Metastatic Soli... Pancreatic Aden... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors | NCT03889275 | Advanced Solid ... | MEDI5395 Durvalumab | 18 Years - 101 Years | MedImmune LLC | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC | NCT06346808 | Pancreatic Canc... | Oncolytic virus... | 18 Years - 75 Years | Sichuan University | |
| ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | NCT01598129 | Malignant Solid... | ONCOS-102 | 18 Years - | Targovax ASA | |
| Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | NCT00314925 | Carcinoid Neuroendocrine | Seneca Valley V... | 18 Years - | Neotropix | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | NCT04673942 | Solid Tumor, Ad... Cancer Neoplasms Sarcoma Sarcoma,Soft Ti... Chondrosarcoma | AdAPT-001 Checkpoint Inhi... | 18 Years - | EpicentRx, Inc. | |
| Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer | NCT05684731 | Ovarian Cancer | KM1 Chemotherapy | 18 Years - | Tongji Hospital | |
| OH2 Injection in Melanoma | NCT05868707 | Melanoma | OH2 Salvage chemoth... | 18 Years - | Binhui Biopharmaceutical Co., Ltd. | |
| Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | NCT00794131 | Advanced Cancer... | GL-ONC1 | 18 Years - | Genelux Corporation | |
| OH2 Injection in Combination With HX008 for Melanoma. | NCT04616443 | Melanoma | OH2 injection HX008 injection | 18 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | NCT05124002 | Cholangiocarcin... | Recombinant Hum... HAIC of FOLFOX | 18 Years - | Beijing Tsinghua Chang Gung Hospital | |
| Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. | NCT01721018 | Malignant Pleur... | HSV1716 Intra-p... | 18 Years - | Virttu Biologics Limited | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer | NCT05232136 | Non-muscle-inva... | OH2 injection | 18 Years - 80 Years | Binhui Biopharmaceutical Co., Ltd. | |
| Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717699 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma | NCT04217473 | Metastatic Mela... | TILT-123 | 18 Years - 75 Years | TILT Biotherapeutics Ltd. | |
| A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | NCT05961111 | Sarcoma Carcinoma Digestive Cance... Breast Cancer Lung Cancer Brain Cancer Melanoma Gynecologic Can... Head and Neck C... Kidney Cancer | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT02620423 | Pancreatic Aden... | REOLYSIN® Chemotherapy Gemcitabine Irinotecan Leucovorin 5-fluorouracil Pembrolizumab | 18 Years - | Oncolytics Biotech | |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | NCT05346484 | Solid Tumor Solid Carcinoma Solid Tumor, Ad... Metastatic Canc... Advanced Solid ... Cholangiocarcin... Bile Duct Cance... | CF33-hNIS Pembrolizumab | 18 Years - | Imugene Limited | |
| "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | NCT06067061 | Triple Negative... | Atezolizumab + ... | 18 Years - | Institut Curie | |
| A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | NCT05602792 | Advanced Solid ... Sarcoma HNSCC Breast Cancer Esophagus Cance... NSCLC Non-melanoma Sk... | T3011 T3011 T3011 T3011 T3011 T3011 T3011 | 18 Years - | ImmVira Pharma Co. Ltd | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors | NCT05851456 | Osteosarcoma Sarcoma Sarcoma,Soft Ti... Bone Tumor | Recombinant onc... | 14 Years - 75 Years | Shanghai Yunying Medical Technology | |
| A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors | NCT05136937 | Solid Tumor Advanced Cancer | Oncolytic Virus... | 18 Years - | Wuxi People's Hospital | |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | NCT05733611 | Refractory Meta... pMMR MSS | RP2 RP3 atezolizumab bevacizumab | 18 Years - | Replimune Inc. | |
| ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | NCT01598129 | Malignant Solid... | ONCOS-102 | 18 Years - | Targovax ASA | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | NCT05561491 | Melanoma | ONCOS-102 Balstilimab | 18 Years - | Targovax ASA | |
| GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | NCT06265025 | Head and Neck C... Malignant Melan... Colorectal Canc... Renal Cell Carc... Cervical Cancer Breast Cancer | GM103 (Part A) GM103 (Part B) GM103 and Pembr... | 18 Years - | GeneMedicine Co., Ltd. | |
| A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | NCT06283303 | Colorectal Canc... | T3011 hepatic a... toripalimab regorafenib | 18 Years - | China Medical University, China | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | NCT05561491 | Melanoma | ONCOS-102 Balstilimab | 18 Years - | Targovax ASA | |
| Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease | NCT04685499 | Head and Neck S... | OBP-301 Pembrolizumab | 18 Years - | Weill Medical College of Cornell University | |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | NCT04725331 | Metastatic Canc... Soft Tissue Sar... Merkel Cell Car... Melanoma Triple Negative... Non Small Cell ... | BT-001 Pembrolizumab [... | 18 Years - | Transgene | |
| Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer. | NCT03252808 | Pancreatic Canc... Pancreatic Canc... | TBI-1401(HF10) Gemcitabine Nab-paclitaxel TS-1 | 20 Years - | Takara Bio Inc. | |
| Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor | NCT05644509 | Advanced Solid ... | Oncolytic Virus... | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas | NCT05928962 | Malignant Melan... | Recombinant Hum... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Trial of C134 in Patients With Recurrent GBM | NCT03657576 | Glioblastoma Mu... Anaplastic Astr... Gliosarcoma of ... | C134 | 18 Years - | University of Alabama at Birmingham | |
| OH2 Oncolytic Viral Therapy in Solid Tumors | NCT03866525 | Solid Tumor Gastrointestina... | OH2 injection, ... | 18 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717699 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | NCT01394939 | Colorectal Carc... CRC | JX-594 Irinotecan | 18 Years - | SillaJen, Inc. | |
| First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | NCT05648006 | Advanced Colore... | OH2 Capecitabine Bevacizumab | 17 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | NCT00438009 | Stage IV Melano... | Coxsackievirus ... | 18 Years - | Viralytics | |
| OH2 Oncolytic Viral Therapy in Central Nervous System Tumors | NCT05235074 | Central Nervous... | OH2 injection | 18 Years - | Binhui Biopharmaceutical Co., Ltd. | |
| A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer | NCT06283303 | Colorectal Canc... | T3011 hepatic a... toripalimab regorafenib | 18 Years - | China Medical University, China | |
| Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder | NCT02723838 | Muscle-invasive... | REOLYSIN® Gemcitabine Cisplatin | 18 Years - | Oncolytics Biotech | |
| Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717712 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | NCT04301011 | Solid Tumor Microsatellite ... HPV Positive Or... Cervical Cancer Melanoma (Skin) Cutaneous Squam... Mesothelioma Renal Cell Carc... Oropharynx Canc... | TBio-6517 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
